Tigecycline pharmacokinetics in subjects with various degrees of renal function.

The pharmacokinetic parameters of tigecycline were assessed in subjects with severe renal impairment (creatinine clearance <30 mL/min, n = 6), subjects receiving hemodialysis (4 received tigecycline before and 4 received tigecycline after hemodialysis), and subjects with age-adjusted, normal renal function (n = 6) after administration of single 100-mg doses. Serial serum and urine samples were collected and assayed using validated liquid chromatography with tandem mass spectrometer (LC/MS/MS) methods. Concentration-time data were then analyzed using noncompartmental pharmacokinetic methods.

Evaluation of a potential tigecycline-warfarin drug interaction.

Study Objective: To evaluate the potential for a clinically significant drug interaction between tigecycline and warfarin by using pharmacokinetic and anticoagulant assessments.

Design: Open-label, nonrandomized study.

Setting: Inpatient clinical pharmacology unit.

Absence of an interaction between tigecycline and digoxin in healthy men.

Study Objective: To evaluate a potential interaction between tigecycline and digoxin using pharmacokinetic and pharmacodynamic assessments.

Design: Open-label, three-period, one-sequence crossover study.

Setting: Hospital-affiliated, inpatient clinical pharmacology unit.